Clinical Trials in the UK / NCT07081503
Recruiting
Phase 1
Phase 1 Study of ADX-626 in Healthy Participants
NCT07081503 · tracked via the Priya Life Science UK tracker
Condition(s) studied
Healthy Adult Participants
Investigational drug(s) / intervention(s)
ADX-626Placebo
ADX-626: siRNA duplex oligonucleotide
Placebo: Saline
Study summary
This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).
Eligibility
Key Inclusion Criteria:
* Age 18 to 45 years at the time of informed consent
* Males or women of non-childbearing potential (WONCBP)
* Willing to comply with all study requirements while participating
* Suitable venous access for blood sampling.
* Body weight ≥ 50 kg and a body mass index (BMI) ≤25 kg/m2
* Normal laboratory results including liver enzymes, hemoglobin, platelet count, and coagulation parameters
* Willing to use acceptable contraception methods if applicable
Key Exclusion Criteria:
* Significant medical condition such as hypertension, diabetes, cardiovascular disease, or cancer
* History of bleeding or coagulation disorders, prior instances of major bleeding, or a family history of bleeding disorders.
* Current infection
* Participation in an interventional drug study within the last 90 days
Primary outcome measure(s)
- Safety of ADX-626 in Healthy Participants — Day 1 to Day 365
Incidence, relationship and severity of adverse events and serious adverse events
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Richmond Pharmacology | London | United Kingdom | Recruiting |
More ADARx Pharmaceuticals, Inc. trials in the UK
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
Recruiting
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07081503 on ClinicalTrials.gov ↗ ← All trials in the UK